Protein aggregation in Huntington's and Parkinson's disease: Implications for therapy

Molecular Medicine Today

Volumn 6, Issue 10, 2000, Pages 387-391

  Wanker, Erich E ^a  

^a MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; ATAXIN 1; CASPASE; CELL PROTEIN; CHAPERONE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HUNTINGTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; POLYGLUTAMINE; PROTEASOME; TATA BINDING PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG;

ARTICLE; DISEASE COURSE; DROSOPHILA; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; LEWY BODY; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FOLDING;

EID: 0033798660     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(00)01761-5     Document Type: Note

References (40)

1. Neuropathological classification of Huntington's disease
2. A novel gene containing a trinucleotide repeat that is unstable on Huntington's disease chromosomes
3. Formation of neuronal intranuclear inclusions (NII) underlies the neurological dysfunction in mice transgenic for the HD mutation
4. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
5. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo
6. Protein fate in neurodegenerative proteinopathies: Polyglutamine diseases join the (mis)fold
7. Structural neurology: Are seeds at the root of neuronal degeneration?
8. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions
9. Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice
10. Neuropathology of Parkinson's disease
11. Mutation in the α-synuclein gene identified in families with Parkinson's disease
12. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease
13. α-Synuclein in Lewy bodies
14. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies
15. Molecular cloning of cDNA encoding an unrecognised component of amyloid in Alzheimer disease
16. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease
17. Both familial Parkinson's disease mutations accelerate α-synuclein aggregation
18. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
19. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: Implications for Huntington's disease pathology
20. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
21. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegnerative disorders
22. Drosophila model of Parkinson's disease
23. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo
24. A cellular model that recapitulates major pathogenic steps of Huntington's disease
25. Neurodegeneration induced by beta-amyloid peptides in vitro: The role of peptide assembly state
26. Receptor-dependet cell stress and amyloid accumulation in systemic amyloidosis
27. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1
28. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila
29. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease
30. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation
31. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription
32. Caspase-8 is required for cell death induced by expanded polyglutamine repeats
33. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegnerative diseases and the elderly
34. The ubiquitin pathway in Parkinson's disease
35. Inhibiting transthyretin amyloid fibril formation via protein stabilization
36. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy
37. α-Synuclein fibrillogenesis is nucleation-dependent
38. Synthetic filaments assemble from C-terminally truncated α-synuclein
39. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology